Table 1.

Study summary information

Study	Description	No. of subjects	No. of occasions	Total no. of samples	Age range (years)
1	Single ascending dose (single oral dose)	20	80	811	23–59
2	Bioavailability (single i.v. infusion followed by single oral dose)	12	24	284	20–35
3	Renal impairment patients (single oral dose)	11	11	131	25–63
4	Immunocompromised patients (single i.v. infusion and 2 subjects were followed with single oral dose after wash-out)	9	11	91	2–17
5	Hepatitis B patients (multiple oral dose)	14	28	231	6–11
6	I.v. infusion multiple dose (multiple i.v. infusion dose)	3	6	128	25–29

Note oral famciclovir and intravenous penciclovir were administered.